Serinus Biosciences
Biotechnology company redefining precision oncology by developing drugs that can target multiple patient populations with a single therapeutic, moving beyond traditional biomarker-defined approaches.
Notes
Serinus Biosciences is a biotechnology company redefining precision oncology by developing therapeutics that can target multiple patient populations with a single drug. The company's approach moves beyond traditional precision medicine paradigms that rely on narrow biomarker-defined patient populations.
The company's platform enables the development of oncology drugs that maintain the benefits of targeted therapy while expanding the potential patient population that can benefit from treatment. This approach aims to address the limitation of traditional precision oncology where drugs often only work in small subsets of patients.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Precision oncology focus
- Multi-population targeting approach
- San Diego, California headquarters
- Novel drug development paradigm
- Expanding beyond biomarker-limited patient populations
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |